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Abstract
Background: Despite the effectiveness of psychosocial programs for recovery from drug use problems, there have
been challenges in implementation of treatment. Internet-based and computerized approaches have been known
to be effective in treatment dissemination. The study purpose is to assess the effects of a web-based psychosocial
relapse prevention program with a multicenter randomized controlled trial.
Methods: Recruitment began in January 2015 for outpatient participants diagnosed with drug abuse or dependence
who have used a primary abused drug in the past year at psychiatric hospitals and a clinic. Participants are randomized
either to a web-based relapse prevention program or a self-monitoring group. The intervention is a web-based
relapse prevention program named “e-SMARPP” that consists of six relapse prevention program modules with
tailored feedback from health care professionals and 8 weeks of self-monitoring. The content is adapted from a
face-to-face relapse prevention program which is based on cognitive behavioral therapy and motivational enhancement.
The primary outcomes are relapse risk assessed by the Stimulant Relapse Risk Scale (baseline, 2-, 5- and 8-month) and the
longest duration of consecutive abstinent days from primary abused drug during the intervention. Secondary outcomes
will include motivation to change, self-efficacy for drug use and craving, abstinent days in the past 28 or 56 days, quality
of life, sense of coherence, cost of substance use, medical cost, retention of treatment and use of self-help group.
Completion, usability and satisfaction of the program will be also assessed to explore feasibility. This study protocol was
approved by the Ethics Committee of The University of Tokyo and each recruiting hospital and clinic.
Discussion: To our knowledge, this study is the first clinical trial to assess the effects of a web-based therapeutic program
for drug users in Japan. If successful, this program is a promising approach for drug user treatment in Japan, where the
stigma toward drug users is strong. The results are also useful for researchers who want to know about programs for
various substances, including methamphetamine.
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Background
Drug use problems and implementation of treatment
Drug use problems have been a serious public health con-
cern and illicit drug dependence is a global burden,
accounting for 0.8 % of global all-cause disability adjusted
life years in 2010 [1]. Drug dependence is highest in the
age cohort of 20–29 years and adversely affects young
adults [1, 2]. In Japan, drug use prevalence and drug
related health problems have been much lower than that
of other countries [3–5]. However, methamphetamine use
disorders are the most prevalent in drug addiction treat-
ment. Moreover, problems related to prescription drug
use and overdose are serious, especially in Japanese female
patients [6–8]. Moreover, outpatient treatment and
community-based support for drug users have been very
poor because of a zero-tolerance policy [6]. Accessible
psychiatric treatment use is very limited, accounting for
about 16 % of drug/alcohol use disorders [9]. Because
pharmacotherapy for drug dependence (e.g., metha-
done, buprenorphine) has not been approved in Japan,
psychosocial approaches are the most important treat-
ment, especially in outpatient settings. However, there
has been a gap between potential treatment needs and
available treatment services, which is also apparent in
other countries. Various reasons have been considered
as barriers to treatment access: (1) limited availability
(e.g., rigid session times, inconvenient locations, costs
for drug users), (2) concerns about confidentiality and
stigmatization and (3) economic and human-resource
limitations for treatment providers [10–14]. Flexible
and accessible treatments are necessary, especially in
Japan as outpatient treatment for drug users is very
limited and societal drug-use stigma is strong.
Treatment using computer and Internet technologies
Therapeutic interventions using computer and Internet
technologies have developed and adapted to various health
problems, including substance use disorders, to address
challenges in treatment implementation [15–17]. Many
computer-assisted or web-based interventions for drug
users which were developed based on psychosocial ap-
proaches demonstrated benefits for abstinence, treatment
retention and cost effectiveness with small to moderate ef-
fect sizes [10, 11, 18–22]. Most of these interventions have
been developed for cocaine or cannabis users in Western
countries. There are few programs for amphetamine-type-
stimulant users and for populations in Asia with different
social backgrounds, even when Internet infrastructure and
computers are generally available [23, 24]. In Japan, there
have been various web and mobile applications to assist in
personal health care, however, evidence-based therapeutic
interventions for drug users remains undeveloped.
Previous work: development of “e-SMARPP”
A new piloted web-based program named “e-SMARPP”
for Japanese drug users was developed by the first author
(AT) based on an existing face-to-face cognitive behav-
ioral relapse prevention program [25], using Moodle
(version 2.6.1) which is an open-source web application
to build e-learning websites [26]. A referenced program
was the Serigaya Methamphetamine Relapse Prevention
Program (SMARPP), which was developed based on the
Matrix Model by one of the authors (TM) and was
widely implemented in Japan [25]. The web-based e-
SMARPP program consisted of three parts: a relapse
prevention program series that included videos, with
narration and subtitles, and assignments in the form of
exercises and a diary; self-monitoring; and information
about drug addiction services. e-SMARPP content is
intended to be user-friendly with minimal text and lim-
ited use of difficult Kanji characters referencing special-
ized medical terminology. User guides in each section
support use. The e-SMARPP website is designed to sup-
port any device, including personal computers, mobile
phones and tablet computers with Internet access. The
website is closed access and only drug users diagnosed
with drug dependence by psychiatrists are provided a
login account from an administrator. The access security
is protected by an individual login/password and secure
socket layer technology. The content of e-SMARPP does
not depend on the type of drug and was developed with
versatility to assist in handling common problems
among drug users. This was because most face-to-face
programs for drug users deal with problems of various
drugs and it was not feasible to gather homogeneous
patients in Japan. The usability and acceptance of e-
SMARPP were reasonable among psychiatric outpatients
and people who had recovered from drug dependence,
but some improvements were suggested [25]. Details of
the development process and findings of the pilot study
were reported in a previous study [25]. In the revision
process after the piloted usability test, content of the
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videos were simplified to focus on approaches to recov-
ery rather than drug adverse effects. Self-monitoring was
improved to be able to record detailed conditions about
drug users if necessary (e.g., drug consumption, forms of
used drugs, triggers of drug use). Functional defects in-
cluding garbled characters on mobile phones were fixed.
Objectives and hypotheses
The aim of this study is to examine the effects of a web-
based cognitive behavioral relapse prevention program,
revised as e-SMARPP, among Japanese psychiatric out-
patients with methamphetamine and other drugs use
problems with a multicenter randomized controlled trial
(RCT) design. The primary hypothesis is that partici-
pants assigned to e-SMARPP will have reduced relapse
risk and maintain a longer duration of consecutive ab-
stinence (days) from a primary abused drug during the
intervention compared to those who were randomized
to self-monitoring only. The secondary hypothesis is that
participants in the e-SMARPP group will report positive
changes in motivation to change, self-efficacy for drug
craving, abstinent days in the past 28 or 56 days (per-
centages and differences in change: pre-post), quality of
life, sense of coherence, cost of alcohol and drug, reten-
tion of treatment, use of self-help group and psychiatric
medical cost. In addition, completion, usability and satis-
faction of the program will be assessed for utilization
and feasibility test. This article describes the study
protocol according to SPIRIT guidelines [27].
Methods
Trial design
Figure 1 shows the design of this study and participant
flow. This study is a two-arm (allocation ratio is one to
one), parallel-group, non-blinded and multicenter ran-
domized controlled trial. Eligible participants are asked
to complete the baseline assessment and are randomly
allocated to either the intervention group or the control
group. All participants in both groups will be provided a
login/password with instructions about how to access
the website and use e-SMARPP during the study. The
participants in the intervention group can access the
complete contents of e-SMARPP, while the control
group can access a part of it: self-monitoring. Each indi-
vidual access account is tied to either group, and as such
participants can use e-SMARPP content included in
their group only. Web-based follow-up assessments are
conducted at 8, 20, 32 weeks after the baseline
assessment.
Participants and setting
The participants are recruited from five psychiatric hospi-
tals and one clinic (National Center of Neurology and
psychiatry, Saitama Psychiatric Medical Center, Kanagawa
Psychiatric Center, Okayama Psychiatric Medical Center,
Tokyo Metropolitan Matsuzawa Hospital and APARI
clinic) that provides treatment for people with substance
use disorder in Japan. The inclusion criteria are: (1) outpa-
tients who were diagnosed with substance use disorder
assessed by DSM-5 (psychoactive substances other than
alcohol and tobacco), (2) those who used a primary
abused drug in the past year and (3) those with access to
the Internet via PC, smartphone or tablet computer and
can exchange e-mail. The exclusion criteria are: (1) pa-
tients with severe physical diseases, (2) patients with high
suicide risk, (3) patients with severe symptoms of
substance-induced psychotic disorder, (4) patients with
impaired cognitive function and (5) those who judged
ineligible to participate in the study by a psychiatrist. We
include various types of participants (form of drugs, previ-
ous and current receiving treatment for drug dependence,
psychiatric comorbidity, pharmacotherapy and sexual
orientation) because we will test adaptation of e-SMARPP
to various drug users in a secondary analysis.
Randomization and blinding
Staff of recruiting institutions will recruit outpatients
who meet inclusion criteria. Eligible participants will be
informed that they will be allocated to either of the two
groups. After baseline assessment, they will be randomly
assigned to either of the two groups using the method of
permuted block, with random block size of four, and
they will be informed their assigned group by the first
author (AT). Randomization will be stratified by institu-
tion. The computer-generated allocation list was made
by an independent researcher (YM) and concealed to
other researchers and participants until the time of
assignment. The enrollment is conducted by the first
author (AT) and the intervention starts immediately.
Researchers and staff who work for recruiting institu-
tions will be blinded. In addition, an independent
researcher (YM) who will not analyze data will download
data from the e-SMARPP database and an independent
research staff person will mask the group variable before
analysis, then researchers (AT and T. Shinozaki) will
analyze data that is blinded to the group variable.
Interventions
Web-based relapse prevention program: e-SMARPP
The website of e-SMARPP is comprised of five modules:
(1) cognitive behavioral relapse prevention sessions
(watching videos, submitting exercises and a weekly
dairy on the website), (2) self-monitoring, calendar that
displays drug use status by color, (3) information, down-
loadable PDF and website links to drug addiction support
services, (4) user guide, how to use the system, frequently
asked questions and a contact form to researchers and (5)
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assessment, which are web-based questionnaires for base-
line and three follow-up assessments.
The main intervention modules are the relapse pre-
vention program sessions and self-monitoring. Content
for the videos and exercises of the relapse prevention
program are taken from the SMARPP workbook and
can be adapted to any type of drug. Each session has
three videos, two exercises and a weekly diary activity
(Table 1). Videos are made in a YouTube format and
embedded in each session (See Fig. 2). Videos are online,
but are unlisted videos and restricted to people who
have the link to the video, so only participants in the
intervention group and researchers can view them. Nar-
ration and subtitles help users understand the content.
Exercises are related to the video content and users will
be expected to complete these after watching the video.
Users will write and submit their own answers through
an Internet text form (See Fig. 3). In addition, users are
expected to write down in the weekly diary their condi-
tion from the last week, current goals, and how they will
plan to spend time over the next week. Writing in the
diary is also done on the Internet through the system.
After submitting the exercise and the weekly diary, users
receive tailored feedback comments from qualified
health care professionals (registered nurse and medical
doctor) who are trained to support patients with
substance use disorders (mainly AT). Feedback com-
ments are based on motivational interviewing skills to
enhance user motivation and to provide individual
support.
The self-monitoring is done in a calendar format,
using a plug-in from Moodle, to provide a function simi-
lar to the self-monitoring process utilized in SMARPP.
Users click on a date in the calendar and select one of
three colors (red, yellow or blue), then that color subse-
quently displays on the date (See Fig. 4). The colors rep-
resent the user’s drug use: red reflecting abuse of the
primary drug; yellow reflecting secondary abuse of other
drugs and alcohol use; and blue indicating no drug and
alcohol use. Instructions and a legend for colors are not
displayed on the Web page to avoid concerns about con-
fidentiality. Participants are provided an explanation
about the colors and how to use the calendar at the time
of study enrollment. This calendar is intended to record
only presence or absence of drug use without quantity
and frequency a day because primary abused drug will
vary and the total quantity will not be able to be
adequately compared. We prioritized a user-friendly sys-
tem without many options for drug names and units. An
optional memo function is provided for personal user
use that records detailed conditions (drug form, quantity
and frequency, triggers, etc.).
Fig. 1 Study design and participant flow
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A self-monitoring calendar is used as a measure to
assess drug use for a period of 28-days before the base-
line and for follow-up assessments like the Timeline
Followback (TLFB) method [28, 29]. Web-based versions
of the TLFB methods have been developed and adapted
to various substances with good reliability and validity
[30–32] and have been used in some intervention stud-
ies [11, 19–21].
e-SMARPP is equipped with some automated func-
tions for participants, including progress tracking and a
notification e-mail when they receive feedback. In the
notification e-mails, a related webpage link is shown and
users can access the webpage directly. For example,
users can view the feedback comment webpage directly
after they click the link in the notification e-mail. Add-
itionally, for researchers who registered on e-SMARPP, a
notification e-mail will be sent when participants submit
an exercise, diary and questionnaire.
Table 1 Content for relapse prevention session of e-SMARPP
1. What is drug dependence?
Video ➢ Mental and physical consequences caused by drug use
(11′ 02″)
➢ Changes in the brain (11′ 39″)
➢ How to stop a drug craving (7′ 43″)
Exercise ■ Think about your pros and cons for drug use and quitting
drugs.
■ Define your drug use situation: when, where, who, why,
what and emotion.
2. Triggers of drug use
Video ➢ Process of craving and drug use (5′ 27″)
➢ Various internal and external triggers of drug craving
(11′ 00″)
➢ Anchors keeping you from drug use (5′ 01″)
Exercise ■ Define your internal and external triggers.
■ Who and what are your anchors?
3. Recovery process; “Just for today”
Video ➢ Process and stage of recovery (12′ 38″)
➢ Safe lifestyle and signs of relapse (10′ 19″)
➢ How to plan a safe daily life (9′ 27″)
Exercise ■ Think of your signs of relapse and barriers to recovery.
■ Plan a safe daily life schedule without drugs.
4. Features of dependence symptoms
Video ➢ Typical features of dependence (9′ 05″)
➢ Typical thoughts and behaviors when people fall for
drugs (12′ 32″)
➢ Justification for relapse (9′ 21″)
Exercise ■ Think of your patterns of thinking and behavior during
drug use
■ Think of your possible justification for relapse
5. Supporters for recovery
Video ➢ Typical internal triggers: “HALT” (hungry, angry, lonely
and tired) (10′ 05″)
➢ To trust and be honest to yourself and others (5′ 41″)
➢ Support from peers and professionals (13′ 39″)
Exercise ■ Think of ways to handle internal triggers.
■ Think of your supporters. Who? How to find?
6. No need to be strong, be smart and practiced
Video ➢ Tips for recovery (6′ 04″)
➢ Review of skills to handle triggers and relapse (12′ 21″)
➢ To accept the way you are, messages from peers (4′ 32″)
Exercise ■ Think of crisis plans when you relapse into drug use.
■ Think of your future when you recover from drug addiction.
Each session also includes a weekly diary activity
Parentheses indicate minutes and seconds of each video
Fig. 2 Screenshot of video
Fig. 3 Screenshot of exercise
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Intervention group
Participants who are assigned to the intervention group
are provided access to the complete contents of e-
SMARPP, including six sessions for cognitive behavioral
relapse prevention and web-based self-monitoring. They
are expected to complete each session over a week in
sequence order by each deadline (each Sunday). For an
8-week intervention period, they are expected to
complete a total six sessions, but they have a 2-week
grace period and are allowed to progress at their own
pace. If they do not complete a session, the session will
be carried over to the next week. Participants will be
expected to record their daily situation of drug use on
the web-based self-monitoring calendar by each deadline
(each Sunday). If they do not go through an expected
session and/or self-monitoring by each deadline, a
researcher will send an e-mail reminder on the next day
(Monday).
Participants continue to receive outpatient treatment
as usual, including medication, face-to-face group or in-
dividual psychosocial treatment programs and counsel-
ing by psychologists and/or social workers. Provided
treatment depends on individual condition. Even if par-
ticipants stop receiving outpatient treatment or change
their primary doctor and hospital, the web-based inter-
vention will not be cancelled.
Control group
Participants who are assigned to the control group are
provided access to a part of the contents of e-SMARPP,
including the web-based self-monitoring and informa-
tion content. Control group participants have no access
to the cognitive behavioral relapse prevention sessions.
Similar to the intervention group, they are expected to
record their daily situation of drug use on the web-based
self-monitoring calendar by each deadline (each Sunday).
If they do not go through the self-monitoring by each
deadline, a researcher will send an e-mail reminder on
the next day (Monday). They will continue to receive
outpatient treatment as usual similar to the intervention
group. After the study period, cognitive behavioral
relapse prevention sessions will be provided if requested.
Measures
Data collection procedure
Table 2 shows an assessment schedule for this study.
Data collection will be conducted through web-based
self-reported questionnaires on the e-SMARPP website
at baseline (T1) and follow-up assessments at 2 (T2), 5
(T3) and 8 (T4) month after the randomization. Partici-
pants will be informed about the follow-up assessments
via e-mail and asked to complete the questionnaire
within 1 week. After 1 week, an additional reminder e-
mail will be sent to non-respondents. If a participant’s
e-mail address changes and an e-mail is not received, a
postcard will be sent as an extra reminder. Participants
will receive a prepaid card for 1000 yen as a reward for
baseline and each follow-up assessment that they
complete.
Primary outcome
The primary outcomes will be relapse risk, assessed
using the Stimulant Relapse Risk Scale (SRRS) [33, 34],
and the longest duration of consecutive abstinence
(days). SRRS was developed to measure multidimen-
sional relapse risk and consists of 35 items measured on
a 3-point Likert scale. The SRRS has five subscales: anx-
iety and intention to use drug (AI), emotionality prob-
lems (EP), compulsivity for drug use (CD), positive
expectancies and lack of control over drug (PL), and lack
of negative expectancy for drug use (NE) [33]. All items
ask about a drug-related situation in the past 1 week.
Examples of the items are “I am anxious about reusing
the drug” (AI), “I cannot control my feeling” (EP), “I
want to obtain the drug even by working illegally” (CD),
“If I use the drug, I would feel invigorated” (PL), and “If
I use the drug, it would badly influence my job” (NE,
inversed item). Higher average scores for total and sub-
scale items indicate higher relapse risk. Its reliability and
validity was confirmed among stimulant drug users in
Japan [33].
We will add another primary outcome, the longest
duration of consecutive abstinence (days), according to
previous studies [19–21]. This is because the cut-off
point of the SRRS has not been confirmed and interpret-
ation of the score is difficult. Additionally, the SRRS was
developed and is only used in Japan, and as such, a more
objective outcome measure is needed. The longest dur-
ation of consecutive abstinence from the primary abused
Fig. 4 Screenshot of self-monitoring calendar
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drug during intervention (56 days) will be counted, using
the self-monitoring calendar and the TLFB method.
We hypothesize that both of the two primary out-
comes will differ significantly between groups.
Secondary outcome
The secondary outcomes (Table 2) will be the following
ten measures.
Motivation to change Motivation to change will be
measured with the Stage of Change Readiness and
Treatment Eagerness Scale-8 version for Drug Use
(SOCRATES-8D) [35, 36]. The SOCRATES-8D consists
of 19 items assessed on a 5-point Likert scale and three
subscales: Recognition, Ambivalence, and Taking Steps.
Examples of the items are “I really want to make
changes in my use of drugs” (Recognition), “Sometimes I
wonder if I am an addict” (Ambivalence) and “I have
already started making some changes in my use of
drugs” (Taking Step). Higher scores indicate higher
motivation to change. Positive correlations have been re-
ported between high scores and the development of
readiness for treatment [37] and engagement in
treatment [38]. Reliability and validity of the Japanese
version of the SOCRATES-8D has been confirmed
[35, 39]. However, a different factor structure (two-
factor structure) was observed in the previous study
[35], so we will use only the total score in this study.
Self-efficacy Confidence (i.e., self-efficacy) in handling
drug use and craving is measured with the Self-efficacy
Scale for Drug Dependence (SSDD) [40]. The SSDD has
two domains: general self-efficacy (GE) and self-efficacy
in specific situations (SS). The GE domain consists of
five items assessed on a 5-point Likert scale from 1 (not
confident) to 5 (confident). Examples of GE items
include, “I can seek help when I have a problem”. The
SS domain consists of 11 items assessed on a 7-point
Likert scale from 1 (not at all confident) to 7 (absolutely
confident). Examples of an SS item includes, “I can han-
dle a drug craving when I am depressed and anxious”.
Higher GE and SS scores mean more confidence in
handling a drug craving.
Abstinence Abstinence from the primary abused drug
will be measured using the following three methods.
Table 2 Assessment schedule of primary and secondary outcomes
Outcome Measurement Baseline
(T1)
2-month
follow-up (T2)
5-month
follow-up (T3)
8-month
follow-up (T4)
Primary outcome
1 Relapse risk SRRS x x x x
2 Longest consecutive duration
of abstinence
Longest duration of consecutive abstinent
days during the intervention #
x
Secondary outcome
1 Motivation to change SOCRATES x x x x
2 Self-efficacy for handling drug use
and craving
Self-efficacy Scale for Drug Dependence x x x x
3 Percentages of abstinent days Abstinent days in the past 28 or 56 days # x x x x
4 Differences in change of abstinent
days
Summed abstinent days in the past 28 days # x x x x
5 Health related quality of life WHOQOL26 x x x x
6 Sense of coherence 3-item sense of coherence scale x x x x
7 Cost of alcohol and drug Self-reported cost of drugs or alcohol in the
last month (yen)
x x x x
8 Treatment retention Yes or no x x x x
9 Self-help group use Yes or no x x x x
10 Psychiatric medical cost Self-reported medical use in the past six months x x
Feasibility and usability outcome
1 Program completion Number of completed weeks x
2 Satisfaction CSQ-8 x
3 Usability and usefulness Original questionnaire x
SRRS Stimulant Relapse Risk Scale, SOCRATES-8D Stage of Change Readiness and Treatment Eagerness Scale-8 version for drug use, CSQ-8, 8-item Client
Satisfaction Questionnaire
#: Self-reported drug use or abstinence assessed by web-based self-monitoring calendar or the Timeline Follow-back method
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First, percentages of abstinent days from the primary
abused drug in the past 28 or 56 days at each assessment
point will be compared. Next, differences in change of
abstinent days from the primary abused drug in the past
28 days between baseline (T1) and follow-up (T2, T3
and T4) will be assessed. Finally, the longest consecutive
abstinent days during the intervention period will be
compared. Abstinent days will be summed using self-
monitoring and the TLFB method.
Quality of life Health related quality of life measured
with WHO/QOL-26 [41], which consist of 26 items
measured on a 5-point Likert scale. There are two items
which asks about an individual’s overall perception of
quality of life (QOL) and their health. The remaining 24
items are divided into four domains: physical domain,
psychological domain, social relationships and environ-
ment. All items ask about respondents’ life in the last 4
weeks. Higher scores indicate higher QOL.
Sense of coherence Sense of coherence (SOC) is con-
sidered to be an individual’s personality as a fundamental
source of coping in stressful events [42]. The SOC of
people with substance use disorder has been considered
lower than that of healthy people [43]. Among people
with mental health problems and substance use disor-
ders, previous studies have revealed that high SOC is
associated with a better ability to cope with stressful life
situations and improved life satisfaction [43, 44] and
high SOC is one of the predictors of treatment success:
treatment retention and drug abstinence [45]. We will
use the University of Tokyo Health Sociology version of
the SOC3 scale (SOC-3-UTHS) [46, 47], which consists
of three items measured on a 7-point Likert scale. A
higher score indicates a higher SOC.
Treatment retention and alternative treatment use
We also will assess participants’ retention of outpatient
treatment and use of self-help group such as narcotics
anonymous.
Cost of substance use and treatment use Total cost of
alcohol and drug use in the past month will be asked sep-
arately. In Japan, methamphetamine is more expensive
than other drugs (above 10,000 yen for use of metham-
phetamine several times). New psychoactive substances
(NPS) are relatively cheap (about 2000 to 5000 yen for
one package).
Cost of psychiatric treatment use in the past 6 months
will also be assessed. We will ask about frequency and
period of psychiatry hospitalization and outpatient treat-
ment, frequency of use of emergency room, total cost of
prescription drugs, frequency and period of specialized
outpatient treatment for drug addiction, the participant’s
income and amount of time required to receive one out-
patient treatment including travel time. We will calculate
total psychiatric medical cost using the annual report of
medical costs by diseases and treatment [48].
Users’ feedback, feasibility, usability
In addition, completion, usability and satisfaction of the
program will be assessed for utilization and a feasibility
test. The intervention completion rate of each group will
be assessed. Usability of the e-SMARPP website will be
assessed using the Web Usability Scale (WUS) [49]. The
WUS consist of 21 items measured on a 5-point scale and
seven subscales: ease of use, ease in understanding struc-
ture, ease in reading, response speed, favorable, helpful-
ness and credibility. The subscale average score will be
calculated, higher score indicates higher website usability.
Usability of e-SMARPP contents will be assessed using
original questionnaires. Example of questions include,
“What is the most useful/unuseful content?”, “Are videos
easy to use? (with options ranging from very easy to very
difficult)” and “How long does it take to complete one
exercise?”. Perceived program satisfaction will be assessed
using the Client Satisfaction Questionnaire 8-item version
(CSQ-8) [50]. CSQ-8 consists of eight items measured on
a 4-point scale. A higher score indicates a higher satisfac-
tion with service use.
Participant characteristics
At the baseline assessment, sociodemographic informa-
tion will be gathered including age, sex, marital status,
cohabitation status, educational history, employment
status and Internet use (use days per week, hours per
day and main devices to access).
Information about history of drug use will be also
asked. The primary problematic drug will be asked. Drug
use in the past 28 days will be collected using the self-
monitoring calendar based on the TLFB method. In
addition, we assess first-abused drug, onset age of any
drug abuse and the primary drug abuse, polydrug abuse
(yes/no), abstinence duration calculated from the day
when they last used a drug, experience of past arrest
(yes/no), past experience in a correctional facilities (yes/
no), and self-reported psychiatric comorbidity with an
option to select a diagnosis based on the International
Classification of Diseases-10. Similarly, we evaluate his-
tory of treatment in several ways: duration of psychiatry
outpatient ward, number of psychiatry hospitalization,
specialized behavioral treatment for drug problems in
the past (yes/no), and self-help group use (yes/no).
In order to assess severity of drug use problems, we use
the Japanese version of the Drug Abuse Screening Test
(DAST-20), which consists of 20 binary items [51, 52]. All
items will ask participants’ drug use condition in the past
year. Total score ranges from 0 to 20 and a high score
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represents a severe condition. The cutoff score for drug
use disorders is suggested as 5/6 with maximum sensitiv-
ity and specificity [53–55], although an optimal cutoff
score has not confirmed in different populations and cul-
ture. It is also suggested that a score of 16 or greater be
considered to indicate a very severe dependence condition
[56]. Furthermore, the Kessler-6 scale consisting of six
items measured on a 5-point scale will be used to assess
psychological distress [57, 58]. A total score ranging from
0 to 24 and a high score indicates severe distress. The
optimal cut-off point is considered 4/5 for a mood and
anxiety disorder [59].
Sample size
Sample size is assumed for two primary outcome variables
(relapse risk and the longest duration of abstinence) to
detect a medium effect size of d = 0.4 based on previous
studies for drug users. As for the first primary outcome
(relapse risk), the effect size between pre and post inter-
vention was d = 0.39 in a study conducting a relapse pre-
vention program in Japan [60]. On another primary
outcome (the longest duration of abstinence), the effect
size between the intervention group and control group
after the intervention was reported as d = 0.45 in a study
conducting for computer-assisted cognitive behavioral
therapy [19]. We estimated a sample size of 100 per group
(total 200), assuming α = 0.05 and a power (1 - β) = 0.08.
Attrition rate and non-completion rate was reported as
relatively high (about 10–45 %) in previous studies of
computer-assisted and web-based intervention for drug
users [11, 19, 61]. However, we did not include additional
samples because we expect a low attrition rate because all
the participants will be outpatients motivated to seek
treatment and we will send email reminders to follow up.
Statistical analysis
Primary analysis
The primary analysis for the SRRS score will be on an
intention-to-treat basis, using mixed-effect models. We
will use all obtained data at the 2, 5 and 8 months
assessment without imputation, assuming the missing
mechanism will be at random given observed data
within the groups. We will include the following vari-
ables as fixed effects: the group, time, the baseline scores
and the interaction of group and time. Time will be
coded as months after the baseline assessment, giving
values of 0, 2, 5 and 8. We will also include random
effects of participants for intercept and time. The effect
of the intervention will be assessed by a test of hypoth-
esis that a time and group interaction equals 0. To help
interpretation in terms of effect size, Cohen’s d between
groups and 95 % confidence intervals will be calculated
at each assessment point; the values of 0.2, 0.5 and 0.8
are considered as small, medium and large effect,
respectively [62]. The longest consecutive abstinent days
from the primary abused drug during intervention will
be compared using t-test. Also, we will calculate a
Cohen’s d for the longest consecutive abstinent days.
When there are significant differences in both of the
two primary outcomes between groups with a level of
5 % in the two-sided test, the intervention will be con-
sidered effective. Analyses will be conducted using SPSS
Statistics Ver. 22.
Sensitivity analysis
In order to assess the sensitivity of the results due to the
assumption of a missing mechanism, we will conduct
complete case analysis using the inverse probability
weighted generalized estimating equation (IPW-GEE), as-
suming the missing data will be missing at random given
observed outcome and time-dependent covariates. IP
weights at each assessment will be estimated by pooled lo-
gistic models for the probability of not dropping-out from
the follow-up, conditional on the measured risk factors
and groups; weights are the reciprocal of the estimated
probability. Additionally, we will use IPW-GEE to assess
effect of the intervention when the definition of abstin-
ence is changed: (1) complete abstinence from all sub-
stances including the non-primary abused drug and
alcohol and (2) the longest duration of consecutive abstin-
ence in the past 28 days instead of the intervention period
(56 days).
Subgroup analysis
The effect of the intervention will be assessed by sub-
groups because the effect may vary depending on spe-
cific population. The participants will be divided by the
primary abused drug (i.e., methamphetamine, NPS and
prescription drugs), sex, severity of drug addiction
(DAST-20 score: 0–5, 6–15, 16–20), the duration of ab-
stinence at the baseline assessment (<1 month, 1–6
months, 7–12 months) and whether receiving face-to-
face behavioral therapy or not.
Cost effectiveness analysis
Health economic evaluation will be undertaken using
data generated within the present trial, to provide infor-
mation on the ‘value’ of allocating resources to the e-
SMARPP (plus usual care) strategy over self-monitoring
(plus usual care). The research question regarding the
economic evaluation is, ‘Is e-SMARPP potentially a cost-
effective means of helping abuse drug users to increase
abstinent days? Specifically, we will employ a cost-
effectiveness analysis (CEA) framework, and the results
of analysis will be summarized as an incremental cost-
effectiveness ratio (ICER). A within-trial analysis will
evaluate cost-effectiveness from a patient and institu-
tional perspective. Sensitivity analysis will be undertaken
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for parameter uncertainty of benefits measures and as-
sumptions to calculate average costs. Subgroup analysis
will be of great interest to make policy recommendations
for a more targeted approach. Subgroups categorized by
variables set in the main trail analysis, e.g., types of
abuse drug primarily used, will be adopted for this sub-
group analysis in an economic evaluation.
Data monitoring
The research members who have an e-SMARPP account
(AT, YM, NK and TM) will monitor the data. The first
author (AT) will manage participants’ progress and com-
pletion of the intervention and the follow-up assessments.
The members will share information about recruitment
progress and data collection every month.
Information of adverse events including hospitalization,
arrest and death will be collected from the participants’
primary doctor during the intervention. Additionally, par-
ticipants will be asked about subjective harmful effect (i.e.,
craving, mental distress) when they use e-SMARPP at the
follow-up assessment (T2).
Ethics and dissemination
Research ethics and approval
The Ethics Committee of the Faculty of Medicine and
Graduate School of Medicine of the University of Tokyo
and the Ethics Committee of each recruiting hospital and
clinic (National Center of Neurology and psychiatry,
Saitama Psychiatric Medical Center, Kanagawa Psychi-
atric Center, Okayama Psychiatric Medical Center,
Tokyo Metropolitan Matsuzawa Hospital and APARI
clinic) approved this study. Before the baseline survey,
candidates will be fully informed that their participation
is totally voluntary and can withdraw the consent if
they want and they can send a withdrawal e-mail to
researchers and also tell their intention to withdraw to
their primary doctor. Even if they withdraw the con-
sent, they will not receive any disadvantage. In addition,
they will be informed that the findings of this study will
be disseminated without participants’ personal infroma-
tion via publication and website. Face-to-face informed
consent will be conducted (AT) and signed consent
forms will be obtained from all participants. The partic-
ipants will be told that the web-based program does
not provide emergency support verbally and on the
website and will be encouraged to use proper medical
services or talk to their primary doctor in case of an
emergency. If a researcher becomes aware of an emer-
gency condition (e.g., imminent suicide intention, vio-
lence) through e-SMARPP, the researcher will consult
with the participant’s primary doctor. All data collected
in this study is securely stored without the participants’
personal information (name, address, etc.). Access to
the data is encrypted and limited to research staff
named on the ethics protocol.
This study protocol was registered with the University
Hospital Medical Information Network clinical trial regis-
try (UMIN-CTR), number UMIN000016075. If there are
important modifications of the protocol, we will obtain ap-
proval for the modifications from the Ethics Committee of
the Faculty of Medicine and Graduate School of Medicine
of the University of Tokyo and will revise the protocol on
the UMIN-CTR website.
Dissemination of research findings
The study findings will be disseminated via publications
in peer-reviewed international journals, the e-SMARPP
website and a research report submitted to the Pfizer
Health Research Foundation. We will also present the
findings at relevant research conferences, local academic
symposiums and seminars.
Discussion
There are strengths to this study. First, to the best of
our knowledge, this study is the first clinical trial using a
web-based program for drug users in Japan. The ran-
domized design and 8-month follow-up will allow for
conclusive results. Second, the e-SMARPP contents were
developed based on an existing evidence-based face-
to-face program and usability has been confirmed. If
successful, e-SMARPP will be promising approach to
addressing problems of treatment implementation and
will be useful for assisting drug user recovery without
lower costs and ease of use. Finally, the study findings
will be also useful for Asian countries where there
are many amphetamine-type stimulants users and
strong drug-use stigma. This circumstance in Japan
reflects a different situation for drug abuse and policy
from that of Western countries where many web-/
mobile-based programs have been developed for that
context.
There are possible limitations to this study. All data from
participants will be self-reported and affected by situation
and perception of participants. Regarding the program, the
relapse prevention sessions of e-SMARPP requires the
involvement of human resources, and web-therapists who
give feedback comments to users’ homework. This
raises concerns about scalability. More web-therapists
and automated functions using algorithms to support a
personalized program will be required when we dissem-
inate e-SMARPP more widely. Additionally, it is
important to consider whether e-SMARPP is useful and
safe when recruiting drug users who do not receive
other treatment and support. For now, we think e-
SMARPP is an adjunct or a partial replacement for stand-
ard treatment. It is important to consider the possibility of
implementation of e-SMARPP with collaboration from
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primary care and providers of mental health services. The
Internet penetration rate is more than 90 % among people
age 13 to 59 in Japan and it has been increasing year by
year, but the rate is low among people with a low house-
hold income [63]. Individual Internet literacy and com-
puter skills may affect not only usability and completion
of the intervention, but also improvement of drug use
problems in this study. Further revision may be required
to provide a more use-friendly program.
Availability of data and materials
A person who is interested in this study will communi-
cate trial results via publications. The data collected in
this study can be obtained from the first author upon
request.
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